KIF18A-IN-6|cas:2914879-10-8|西域试剂

KIF18A-IN-6,98.39%

产品编号：Bellancom-153065| CAS NO：2914879-10-8| 分子式：C₂₈H₃₇N₃O₅S₂| 分子量：559.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-153065	￥3800.00	杭州北京（现货）
Bellancom-153065	￥6200.00	杭州北京（现货）
Bellancom-153065	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

KIF18A-IN-6

产品介绍

KIF18A-IN-6 (Compound 134) 是一种具有口服活性的 KIF18A 抑制剂，抑制 KIF18A 微管依赖性 ATPase 活性，IC₅₀ 为 0.016 μM。

生物活性

KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC₅₀ of 0.016 μM against KIF18A microtubule-dependent ATPase activity.

体外研究

KIF18A-IN-6 (Compound 134; 7 days) 抑制 JIMT-1、HCC-15 和 NIH-OVCAR3 细胞活力，IC₅₀ 分别为 0.0040、0.0051 和 0.0051 μM。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HCC-15, JIMT-1 and NIH-OVCAR3
Concentration:
Incubation Time:	7 days
Result:	Inhibited cell viability with IC₅₀s of 0.0040, 0.0051 and 0.0051 μM against JIMT-1, HCC-15 and NIH-OVCAR3 cells, respectively.

体内研究
(In Vivo)

KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID Beige mice, HCC15 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice a day for 1 month
Result:	Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively.

Animal Model:	Balb/C nude mice, OVCAR3 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice or once a day for 1 month
Result:	Completely inhibited tumor growth (over 100%) over 30 mg/kg.

体内研究

KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID Beige mice, HCC15 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice a day for 1 month
Result:	Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively.

Animal Model:	Balb/C nude mice, OVCAR3 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice or once a day for 1 month
Result:	Completely inhibited tumor growth (over 100%) over 30 mg/kg.

体内研究

KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID Beige mice, HCC15 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice a day for 1 month
Result:	Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively.

Animal Model:	Balb/C nude mice, OVCAR3 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice or once a day for 1 month
Result:	Completely inhibited tumor growth (over 100%) over 30 mg/kg.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (223.32 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7865 mL	8.9327 mL	17.8654 mL
5 mM	0.3573 mL	1.7865 mL	3.5731 mL
10 mM	0.1787 mL	0.8933 mL	1.7865 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.72 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.72 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。